Keryx Biopharmaceuticals

Keryx Biopharmaceuticals is a commercial-stage biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products for patients with renal disease. The company markets its lead product Auryxia (ferric citrate), an orally available, absorbable, iron-based medicine for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis. Keryx Biopharmaceuticals merged with Akebia Therapeutics.

Employee Rating

4More
StateClosed
TypeSubsidiary
Parent CompanyAkebia Therapeutics
HQNew York, US
Founded1998
Websitekeryx.com
Cybersecurity ratingAMore
Keryx Biopharmaceuticals was founded in 1998 and is headquartered in New York, US

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Keryx Biopharmaceuticals

Jodie Morrison

Jodie Morrison

Interim Chief Executive Officer, Board Member
Melissa Bradford Klug

Melissa Bradford Klug

SVP, Chief Business Officer
Christine Carberry

Christine Carberry

SVP, Chief Operating Officer
Scott Holmes

Scott Holmes

SVP, Chief Financial Officer
John F. Neylan

John F. Neylan

SVP, Chief Medical Officer
Amy B. Sullivan

Amy B. Sullivan

SVP, Corporate Affairs
Show more

Keryx Biopharmaceuticals Office Locations

Keryx Biopharmaceuticals has offices in New York and Cambridge
New York, US (HQ)
Beekman Regent Condominium, 750 Lexington Ave 20th Floor
Cambridge, US
245 First St #1400
Show all (2)

Keryx Biopharmaceuticals Financials and Metrics

Summary Metrics

Founding Date

1998
Keryx Biopharmaceuticals is a subsidiary of Akebia Therapeutics

Keryx Biopharmaceuticals Revenue

Keryx Biopharmaceuticals's revenue was reported to be $60.64 m in FY, 2017
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

5.0m7.0m10.8m13.7m32.0m60.6m

Revenue growth, %

55%26%134%

Cost of goods sold

4.5m37.8m22.0m

Gross profit

9.2m(5.8m)38.7m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

5.0m7.0m10.0m256.0k1.2m2.5m4.2m6.8m9.3m6.3m11.8m15.1m15.0m21.8m25.7m28.0m

Cost of goods sold

76.0k304.0k3.1m1.1m5.1m18.2m4.3m4.4m5.9m9.6m7.4m

Gross profit

1.1m2.2m1.1m5.8m4.2m(11.9m)7.5m10.8m9.1m12.2m18.3m

Gross profit Margin, %

94%88%27%84%45%(187%)64%71%61%56%71%
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

35.3m14.7m55.7m74.3m200.3m111.8m93.5m

Accounts Receivable

834.0k3.7m5.2m8.1m

Prepaid Expenses

534.0k430.0k1.2m4.1m2.8m11.2m

Inventories

7.8m41.9m12.7m28.7m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

43.2m37.8m21.7m21.1m20.2m87.3m55.9m67.7m105.3m92.0m84.1m168.8m131.3m102.2m170.5m155.8m132.2m90.9m140.5m114.0m60.1m49.5m41.1m

Accounts Receivable

1.3m1.4m2.6m4.3m5.1m6.2m8.5m9.2m12.9m15.4m14.6m

Prepaid Expenses

368.0k804.0k524.0k190.0k558.0k1.7m1.3m3.7m1.2m1.2m2.7m3.4m2.8m4.3m2.5m2.2m3.5m9.7m8.6m15.6m11.1m12.1m11.9m

Inventories

918.0k27.2m34.0m36.7m42.2m39.7m24.3m12.6m18.1m26.0m35.4m48.6m58.7m
USDQ2, 2011

Financial Leverage

1.2 x
Show all financial metrics

Keryx Biopharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

Keryx Biopharmaceuticals Online and Social Media Presence

Embed Graph

Keryx Biopharmaceuticals News and Updates

Keryx Biopharmaceuticals Stockholders Approve Merger with Akebia Therapeutics

BOSTON, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced that Keryx stockholders voted in favor of adopting the merger agreement among Keryx and inter…

Keryx Biopharmaceuticals Announces Third Quarter 2018 Financial Results

BOSTON, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced its financial results for the third quarter ended September 30, 2018. The company also review…

Keryx Biopharmaceuticals to Release Third Quarter 2018 Financial Results on Thursday, November 8, 2018

BOSTON, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced that it will release its third quarter 2018 financial results on Thursday, November 8, 2018 at…

Monteverde & Associates PC Files Class Action Lawsuit On Behalf Of Shareholders Of Keryx Biopharmaceuticals, Inc. In The U.S. District Court For The District Of Delaware

NEW YORK, Nov. 5, 2018 /PRNewswire/ -- Notice is hereby given that Monteverde & Associates PC has filed a class action lawsuit in the United States District Court for the District of Delaware, Case No.1:18-cv-01589-LPS, on behalf of public common shareholders of Keryx Biopharmaceuticals,...

Lifshitz & Miller LLP Announces Investigation of Access National Corporation, Engility Holdings, Inc., Floor & Decor Holdings, Inc., Global Blood Therapeutics, Inc., Intrexon Corporation, Keryx Biopharmaceuticals, Inc., Nevada Gold & Casinos, Inc., and Sonic Corp.

NEW YORK, Nov. 1, 2018 /PRNewswire/ -- Access National Corporation (ANCX) Lifshitz & Miller announces investigation into possible breaches of fiduciary duties in connection with the sale of ANCX to Union Bankshares Corporation for 0.75 shares of Union common stock per share. If you are an ...

Keryx Biopharmaceuticals Announces Filing of Definitive Joint Proxy Statement in Connection with Pending Merger with Akebia Therapeutics

Keryx Board Unanimously Supports Merger with Akebia and Encourages Stockholders  to vote “FOR” the Merger Proposals
Show more

Keryx Biopharmaceuticals Frequently Asked Questions

  • When was Keryx Biopharmaceuticals founded?

    Keryx Biopharmaceuticals was founded in 1998.

  • Who are Keryx Biopharmaceuticals key executives?

    Keryx Biopharmaceuticals's key executives are Jodie Morrison, Melissa Bradford Klug and Christine Carberry.

  • How many employees does Keryx Biopharmaceuticals have?

    Keryx Biopharmaceuticals has 189 employees.

  • What is Keryx Biopharmaceuticals revenue?

    Latest Keryx Biopharmaceuticals annual revenue is $60.6 m.

  • What is Keryx Biopharmaceuticals revenue per employee?

    Latest Keryx Biopharmaceuticals revenue per employee is $320.9 k.

  • Who are Keryx Biopharmaceuticals competitors?

    Competitors of Keryx Biopharmaceuticals include Outpost Medicine, Qilu Pharmaceutical and Ruicheng Haihui.

  • Where is Keryx Biopharmaceuticals headquarters?

    Keryx Biopharmaceuticals headquarters is located at Beekman Regent Condominium, 750 Lexington Ave 20th Floor, New York.

  • Where are Keryx Biopharmaceuticals offices?

    Keryx Biopharmaceuticals has offices in New York and Cambridge.

  • How many offices does Keryx Biopharmaceuticals have?

    Keryx Biopharmaceuticals has 2 offices.